Licensed vaccine
FluMist Quadrivalent
FDA-licensed vaccine · MedImmune, LLC · STN 125020
Key facts
| Trade name | FluMist Quadrivalent |
|---|---|
| Proper name | Influenza Vaccine,Live, Intranasal (Quadrivalent, Types A and Types B) |
| Manufacturer | MedImmune, LLC |
| Submission tracking number (STN) | 125020 |
| FDA product areas | Biologics, Flu Vaccine |
| Recent FDA documents | June 30, 2023 Approval Letter - FluMist Quadrivalent, January 12, 2023 Approval Letter - FluMist, July 27, 2022 Approval Letter - FluMist Quadrivalent, Package Insert - FluMist Quadrivalent, July 20, 2021 Approval Letter - FluMist, July 9, 2020 Approval Letter - FluMist, April 14, 2020 Approval Letter - FluMist, July 15, 2019 Approval Letter - FluMist, February 28, 2019 Approval Letter - FluMist Quadrivalent, August 10, 2018 Approval Letter - FluMist Quadrivalent, May 15, 2018 Approval Letter - FluMist Quadrivalent, March 17, 2017 Approval Letter - FluMist Quadrivalent |
| FDA page updated | Jul 6, 2023 |
| FDA product page | fda.gov |
At a glance
- 10–99 FDA approval letters
- 10–99 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: